| __timestamp | CRISPR Therapeutics AG | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 21263000 |
| Thursday, January 1, 2015 | 12573000 | 18890000 |
| Friday, January 1, 2016 | 42238000 | 15295000 |
| Sunday, January 1, 2017 | 69800000 | 12944000 |
| Monday, January 1, 2018 | 113773000 | 13599000 |
| Tuesday, January 1, 2019 | 179362000 | 30391000 |
| Wednesday, January 1, 2020 | 266946000 | 13020000 |
| Friday, January 1, 2021 | 438633000 | 16287000 |
| Saturday, January 1, 2022 | 461645000 | 19943000 |
| Sunday, January 1, 2023 | 387332000 | 21042000 |
| Monday, January 1, 2024 | 320653000 |
Unleashing insights
In the ever-evolving landscape of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, CRISPR Therapeutics AG and Vericel Corporation have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, CRISPR Therapeutics AG has consistently increased its R&D spending, peaking in 2022 with a staggering 4.6 times the amount spent in 2014. This reflects a robust growth trajectory and a strong focus on pioneering genetic therapies.
In contrast, Vericel Corporation's R&D expenditure has remained relatively stable, with a modest increase of about 10% over the same period. This suggests a more conservative approach, potentially focusing on optimizing existing technologies. As the biotech industry continues to expand, these spending patterns highlight the strategic priorities of each company, offering insights into their future directions.
Research and Development Expenses Breakdown: United Therapeutics Corporation vs CRISPR Therapeutics AG
Analyzing R&D Budgets: Insmed Incorporated vs CRISPR Therapeutics AG
R&D Spending Showdown: BioMarin Pharmaceutical Inc. vs CRISPR Therapeutics AG
Comparing Innovation Spending: CRISPR Therapeutics AG and Protagonist Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs Mesoblast Limited
CRISPR Therapeutics AG vs Galapagos NV: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs BioCryst Pharmaceuticals, Inc.
Research and Development Investment: Vericel Corporation vs MannKind Corporation
Analyzing R&D Budgets: Vericel Corporation vs Wave Life Sciences Ltd.
Analyzing R&D Budgets: Vericel Corporation vs Supernus Pharmaceuticals, Inc.
Comparing Innovation Spending: Vericel Corporation and Xencor, Inc.